PT  - JOURNAL ARTICLE
AU  - MARIA AURORA CARLEO
AU  - FILOMENA DI MARTINO
AU  - ANNALISA DEL GIUDICE
AU  - MIRIAM GARGIULO
AU  - GIOVANNI PARRELLA
AU  - PIETRO ROSARIO
AU  - VINCENZO SANGIOVANNI
AU  - ROSARIA VIGLIETTI
AU  - VINCENZO ESPOSITO
AU  - ANTONIO CHIRIANNI
TI  - Different Impact of Anti-retroviral Regimen Containing Protease Inhibitors on Development of HIV-related Kaposi Sarcoma
DP  - 2015 Jan 01
TA  - In Vivo
PG  - 133--136
VI  - 29
IP  - 1
4099  - http://iv.iiarjournals.org/content/29/1/133.short
4100  - http://iv.iiarjournals.org/content/29/1/133.full
SO  - In Vivo2015 Jan 01; 29
AB  - Background: The incidence of Kaposi's sarcoma (KS), an AIDS-related malignancy, has dramatically decreased in the Highly Active Anti-retroviral Therapy (HAART) era. However, KS remains the second most frequent tumor in HIV-infected patients worldwide and has become the most common cancer in the sub-Saharan Africa. Experimental studies have demonstrated a direct anti-neoplastic effect of HAART, and overall of protease inhibitors (PIs), on KS. Case Report: We describe five cases of KS in HIV-infected patients on HAART regimen, containing PIs as atazanavir/r (ATV/r), darunavir/r (DRV/r), lopinavir/r (LPV/r) and fosamprenavir (fAMP/r). Conclusion: Clinical and experimental observations support the hypothesis that PIs may play an important role in prevention and treatment of KS. In our study, the treatment with PIs of recent generation was not protective against the development of KS. Therefore, it could be necessary to re-evaluate the therapeutic effects of PIs and their role in the development and treatment of KS in HIV-infected patients.